Pricing Log in Create free account
Saturday 17 October 2026 Export RPRX’s income statement to Excel — free account

Royalty Pharma PLC

RPRX Healthcare Biotechnology

Royalty Pharma PLC’s revenue for fiscal 2025 (year ended December 2025) was $2.4 billion, up 5.06% from fiscal 2024. In the quarter to June 2026, revenue grew 16.5%, EPS fell 40.0%, free cash flow grew 31.6% and total debt rose 12.0%, each against the same quarter a year earlier. Dividend growth for five consecutive years.

61.29 1.67 +2.80%
Market cap
$34.3B
P/E
42.3×
Fwd P/E
21.9×
Dividend yield
1.51%
F-score
5/9
Altman Z
1.61
Beneish M
−2.83
Dividend safety
37/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 92.82
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell 3 9 7 2 2 2 4 3 1 2 2 1
Insider Ownership 6.27%

Capital & Financial Ratios $m

Market Cap 34,280.00
Revenue 2,536.00
Net Income 1,346.87
Free Cash Flow 1,310.08
Net Debt 8,124.91
Current Ratio 2.80 (at or above 1.5: strong)
Debt/Equity 0.92
P/E ratio 42.27 (above 35: high)
Fwd P/E 21.90
P/S ratio 10.76 (above 10: high)
P/B ratio 2.79
Past 5Y EPS Growth (3.18%) (below 0%: weak)
This Y EPS Growth 10.17%
Next Y EPS Growth 8.99%
Next Y revenue growth 47.38% (at or above 10%: strong)
Next 5Y EPS Growth 10.64%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 14.0×, against a ten-year median of 9.6×; over the ten years it ranged from 7.3× in 2023 to 14.0× in 2026.
P/E against its own 10 years 69.80%
10-year low 10-year high
P/S against its own 10 years 99.31%
10-year low 10-year high
P/B against its own 10 years 99.31%
10-year low 10-year high
EV/Sales against its own 10 years 99.31%
10-year low 10-year high
EV/FCF against its own 10 years 73.34%
10-year low 10-year high

Dividends

Payout Ratio 0.64
Annual Dividend Rate 0.93
Annual Dividend Yield 1.51%
total individual payouts
2028 Powerpack
2027 Powerpack
2026 1.01
0.24
0.24
0.24
2025 0.88
0.22
0.22
0.22
0.22
2024 0.84
0.21
0.21
0.21
0.21
2023 0.80
0.20
0.20
0.20
0.20
2022 0.76
0.19
0.19
0.19
0.19
2021 0.68
0.17
0.17
0.17
0.17
2020 0.30
0.15
0.15
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 495 987 637 837
Receivables 22 27 29 31
Inventory — — — —
Other 756 788 861 896
1,274 1,802 1,528 1,765
2023 2024 2025 Q'26
Payables 15 13 19 36
ST’ Debt — 998 380 380
Other 11 69 53 16
161 1,254 636 631

Compound Annual Growth %

10y 5y 3y
Sales — 2.30% 2.06%
Cash Flow — 4.12% 5.11%
Earnings — (4.59%) 162.07%
Book Value — (0.37%) 0.66%

Revenue $m

Mar Jun Sep Dec Year
’26 631 674 — — —
’25 568 579 609 622 2,378
’24 568 537 565 594 2,264
’23 684 538 536 596 2,355
’22 562 536 573 566 2,237
’21 573 555 586 576 2,289
’20 501 511 538 572 2,122
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 718 728 — — —
’25 596 364 703 827 2,490
’24 665 658 704 743 2,769
’23 1,034 608 574 773 2,988
’22 460 575 539 570 2,144
’21 526 532 470 490 2,018
’20 471 489 509 566 2,035
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 266 477 — — —
’25 595 363 (259) 827 2,490
’24 579 (70) (491) 2,734 2,751
’23 432 547 122 773 2,988
’22 460 400 (777) 2,040 2,123
’21 23 351 (866) 318 (174)
’20 372 14 (294) (239) (148)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 0.53 0.03 — — —
’25 0.41 0.05 0.51 0.38 1.37
’24 0.01 0.17 0.92 0.35 1.45
’23 0.56 0.38 0.12 0.83 1.88
’22 0.09 0.50 0.24 (0.86) 0.07
’21 0.11 0.73 0.17 0.01 1.02
’20 — 0.73 0.48 0.28 1.61
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.5
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — 34.80 34.86 36.15 25.92 24.05 25.40

Analyst estimates 2026–2028

Powerpack
High — — — — 56.50 53.23 44.75 39.92 31.66 41.24
People
People Employees — — — 35 — — — 89 99 100
Revenue/emp, $m — — 0.00 51.84 0.00 0.00 0.00 26.46 22.86 23.78
Income, $m
Income, $m Revenue — — 1,795 1,814 2,122 2,289 2,237 2,355 2,264 2,378
Gross margin, % — — 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
EBT — — 1,518 2,461 1,702 1,241 230 1,700 1,331 1,324
EBT margin, % — — 84.57 135.67 80.19 54.21 10.28 72.20 58.79 55.68
Net income — 0 1,518 2,461 1,702 1,241 230 1,700 1,331 1,324
Depreciation — — 46 37 35 43 27 20 20 32
Per share, $
Per share, $ Revenue — — 0.00 4.83 5.65 5.52 5.11 5.26 5.05 5.53
Earnings — — — 6.56 1.61 1.02 0.07 1.88 1.45 1.37
Cash flow — — 0.00 4.44 5.42 4.86 4.90 6.68 6.18 5.79
Capex — — 0.00 (4.58) (5.81) (5.28) (0.05) 0.00 (0.04) 0.00
Free cash flow — — 0.00 (0.14) (0.39) (0.42) 4.85 6.68 6.14 5.79
Book value — — 0.00 16.36 26.36 24.71 21.75 22.53 23.08 22.60
Shares, m — — — 375 375 415 438 448 448 430
Valuation, ×
Valuation, × P/E — — 66.51 66.51 41.36 39.07 492.50 14.96 17.59 28.62
P/S — — 0.00 0.00 8.85 7.22 7.71 5.37 5.05 6.98
P/B — — 0.00 0.00 1.90 1.61 1.81 1.25 1.11 1.71
EV/Sales — — 0.00 0.00 10.71 9.44 10.12 8.19 7.98 10.48
EV/FCF — — 18.65 18.65 (153.96) (124.27) 10.66 5.77 6.56 7.09
Cash, $m
Cash, $m Operating cash flow — — 1,618 1,667 2,035 2,018 2,144 2,988 2,769 2,490
Capex — — (270) (1,721) (2,182) (2,192) (21) — (18) —
Free cash flow — — 1,349 (54) (148) (174) 2,123 2,988 2,751 2,490
Balance, $m
Balance, $m Working capital — — — 499 2,389 2,707 1,388 1,113 549 892
Total debt — — — 6,266 5,817 7,096 7,116 6,135 7,612 8,951
Net debt — — — 5,926 3,755 4,907 5,380 5,640 6,625 8,313
Shareholders’ equity — — — 6,141 9,896 10,249 9,525 10,084 10,342 9,715
Returns, %
Returns, % ROA — — 0.00 37.73 6.85 3.70 0.25 6.84 4.96 4.07
ROIC — — 0.00 13.59 7.30 5.90 1.29 5.93 4.76 5.41
ROE — — 0.00 29.29 12.16 6.15 0.43 11.57 8.41 7.69
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Royalty Pharma PLC vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ARGX argenex SE $53.2B 29.6× 32.4× +59.46% (above 0%: growing) +88.56% (above 0%: growing) +537.51% (above 0%: growing) 90.60% 32.04% Compare
RVMD Revolution Medicines, Inc. $40.6B — (loss-making) — (loss-making) −77.89% (below 0%: shrinking) n/m −69.98% (below 0%: shrinking) 100.00% 0.00% Compare
ONC BeOne Medicines Ltd. - Sponsored ADR $39.0B 62.6× 40.2× +29.63% (above 0%: growing) +143.68% (above 0%: growing) +117.92% (above 0%: growing) 89.76% 19.06% Compare
RPRX Royalty Pharma PLC $34.3B 42.3× 21.9× +16.50% (above 0%: growing) −40.00% (below 0%: shrinking) +31.57% (above 0%: growing) 100.00% 19.75%
ALNY Alnylam Pharmaceuticals, Inc. $31.3B 39.5× 39.6× +66.86% (above 0%: growing) n/m +152.82% (above 0%: growing) 76.88% 17.93% Compare
ROIV Roivant Sciences Ltd. $24.6B — (loss-making) — (loss-making) −33.55% (below 0%: shrinking) n/m −29.99% (below 0%: shrinking) 80.31% (25,380.93%) Compare
INCY Incyte Corporation $23.0B 13.9× 15.6× +37.72% (above 0%: growing) +39.71% (above 0%: growing) +1,829.52% (above 0%: growing) 93.73% 41.69% Compare
BNTX BioNTech SE Sponsored ADR $22.7B — (loss-making) — (loss-making) −58.53% (below 0%: shrinking) n/m −342.04% (below 0%: shrinking) 8.14% (897.82%) Compare
GMAB Genmab A/S Sponsored ADR $22.6B 29.1× 21.0× +24.86% (above 0%: growing) −9.26% (below 0%: shrinking) −7.69% (below 0%: shrinking) 92.73% 32.47% Compare
Median of peers $28.0B 29.6× 32.4× +27.24% +64.14% +55.12% 90.18% 18.50%

All 614 Biotechnology stocks →

Royalty Pharma PLC (RPRX) key facts

  • Strength: Royalty Pharma PLC’s revenue for fiscal 2025 (year ended December 2025) was $2.4 billion, up 5.06% from fiscal 2024.
  • Royalty Pharma PLC (RPRX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, RPRX traded at $61.29, a market capitalization of $34.3 billion.
  • Royalty Pharma PLC pays an annual dividend of $0.93 per share, a yield of 1.51%, with a payout ratio of 63.8%.
  • Return on equity was 7.69% and debt-to-equity 0.92.
  • Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 1.61 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Royalty Pharma PLC (RPRX) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/RPRX · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com